For instance, the blood and CSF levels of neurofilament light (a promising biomarker for AD diagnosis) has been proved consistent (Fortea et al., 2018; Jack et al., 2018), indicating that it is potential to develop a blood-based, rapid, simple, portable, and easily accessible testing method for the AD screening in community populations. Here, NEFL is linked to Alzheimer disease.